Procedures & recovery · patient guide

Imaging needed for a lymphoma review

For a lymphoma review, the imaging that matters most is the scan that shows disease extent and activity, together with the pathology that confirms the diagnosis. A PET-CT is central to staging many lymphomas, and CT or MRI may be needed for specific sites. What your case needs is decided by the treating haematologist, so send your existing scans and reports rather than arranging new tests first.

Go to the practical guidance ↓
AI illustration: A travel bag, passport, and pen on a marble table with a cityscape and pagoda visible through a large window.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Why the scan alone cannot answer a lymphoma question

A lymphoma review is not a radiology reading in isolation. The treating haematologist needs to connect three things: the tissue diagnosis, the anatomical extent of disease and the activity of the disease. Imaging contributes the last two. Without a confirmed pathology report, a scan showing enlarged nodes or uptake cannot establish which lymphoma subtype is present or which treatment applies.

This is why a useful review starts with what you already have. If a biopsy has been done, the pathology report and the tissue blocks or slides are the foundation. If no biopsy has been taken, the first clinical question is usually whether one is needed and where, not which scan to book. Imaging can guide a biopsy site, but it does not replace the tissue diagnosis.

For many lymphomas, fluorodeoxyglucose PET-CT is used for staging because it shows metabolically active disease across the body. The Lugano classification, published in the Journal of Clinical Oncology, sets out how PET-CT and CT are used in staging and response assessment for lymphoma. That does not mean every patient needs every modality. The subtype, the sites involved and the clinical question change the choice.

The imaging a haematologist is likely to ask about

Rather than a fixed list, think in terms of what each scan answers. A PET-CT addresses disease distribution and activity, and is often used as the baseline against which later response is judged. A contrast-enhanced CT of the neck, chest, abdomen and pelvis can define node size and organ involvement, and may be used where PET-CT is not available or not indicated. MRI is useful for specific areas such as the brain, spinal cord or bone, where its soft-tissue detail matters more than a body survey.

Some subtypes behave differently. In Hodgkin lymphoma and in FDG-avid non-Hodgkin lymphomas, PET-CT is generally the reference for staging and end-of-treatment assessment. In some indolent lymphomas, CT-based measurement may be sufficient for parts of the pathway. A bone marrow biopsy is a separate procedure, not imaging, and whether it is needed depends on the subtype and stage.

Echocardiography is not a lymphoma staging scan, but it is sometimes requested before certain chemotherapy regimens to assess cardiac function. That decision belongs to the treating team. If you have had one, include the report; if not, ask whether it will be required rather than arranging it yourself.

What to send before anyone comments on your case

The most useful package is a clear chronology plus the original files. Scans sent as compressed photographs of a screen are hard to interpret; DICOM files on a disc or a secure download link are what a radiology department can actually read. Reports alone tell the reviewer what someone concluded, not what the images show.

A practical set for a lymphoma review includes: the pathology report with the subtype and any markers reported; the biopsy slides or blocks if the receiving hospital wants to re-review them; the most recent PET-CT and CT images with reports; any MRI or other site-specific imaging; and blood counts, liver and kidney function and other recent laboratory results. A short summary of treatment so far, including dates and regimens, helps the reviewer place the scans in context.

You do not need to send a complete archive at first contact. A brief summary of the diagnosis and your main question is enough to start, and the team can then tell you which files matter. Avoid sending passport numbers or payment details through an initial enquiry.

Re-review of scans and pathology in China

Hospitals commonly want to look at the original imaging rather than rely on an outside report, and pathology re-review is a recognised step in lymphoma care because subtype classification affects treatment. Whether a particular Chinese hospital will re-read your scans, re-cut your blocks or accept the outside pathology report is a question for that hospital. Ask directly, and ask what format they require.

There is a practical limit worth understanding. A records-based opinion can discuss the images and pathology you provide and comment on the likely next step, but it cannot confirm fitness for a specific treatment, final eligibility or hospital acceptance. Those decisions follow the treating hospital's own assessment, which may include examination and further tests in person.

If your question is whether your current imaging is adequate for a treatment decision, say so explicitly. The reviewer can then tell you whether the existing PET-CT and pathology are sufficient for a meaningful opinion or whether a gap needs filling.

Questions to put to the treating team

Specific questions get specific answers. Ask which imaging the team considers necessary for your subtype and stage, whether your existing PET-CT is recent enough to use as a baseline, and whether the original images or only the report are needed. Ask whether pathology slides or blocks should travel with you and in what condition.

Ask, too, about timing and logistics that only the provider can confirm: how long scan review takes at that hospital, whether a new scan would be arranged during the same visit, and what the written plan and quote include. These are not things to assume from another country's practice or from a general article.

If you are comparing hospitals, compare on the same basis: what each one asks you to send, what it will review, and what it will confirm in writing. A clear answer about the imaging pathway is more useful than a broad promise of a comprehensive assessment.

A sensible next step

Start with your diagnosis, the date and type of your most recent imaging, and the one decision you need help with. ChinaSpecialistCare's free initial case review checks the available records and your main question, identifies what is missing and suggests the relevant next step; it is not a diagnosis or a promise of acceptance. If a records-based specialist opinion would help before you travel, a proxy consultation is available but optional. The hospital decides suitability, and its own consultation and imaging charges are separate from coordination fees.

For the clinical background, the Lugano classification and related guidance are the relevant references. For care planning, see the lymphoma treatment page and the haematology specialty page.

Related treatment reference

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. Cheson BD et al., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, Journal of Clinical Oncology
  3. National Cancer Institute, Adult Non-Hodgkin Lymphoma Treatment (PDQ)
  4. National Cancer Institute, Hodgkin Lymphoma Treatment (PDQ)

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.